

on Vaccine Research

FINAL PROGRAM

SUNDAY, MAY 5, 2002

7:00 – 9:00 p.m.

EARLY REGISTRATION

Foyer – International Ballroom

MONDAY, MAY 6, 2002

7:00 – 9:00 a.m.

REGISTRATION

Foyer – International Ballroom

8:30 a.m.

CONTINENTAL BREAKFAST

9:00 a.m.

WELCOME AND INTRODUCTIONS

International A/B/C

KEYNOTE ADDRESS

CME

Moderator: Stanley A. Plotkin, M.D.
Aventis Pasteur/University of Pennsylvania

9:10 a.m.

1. VACCINES AGAINST BIOTERRORISM

Philip K. Russell, M.D.
U.S. Department of Health and Human Services

International A/B/C

9:45 a.m.

QUESTIONS AND ANSWERS

MARY LOU CLEMENTS-MANN MEMORIAL LECTURE IN VACCINE SCIENCES

CME

International A/B/C

Moderator: Peter L. Nara, D.V.M., Ph.D.
Biological Mimetics, Inc.

9:50 a.m.

2. TUBERCULOSIS: PROGRESS IN THE DEVELOPMENT OF A NEW VACCINE AGAINST THE CAPTAIN OF ALL THE MEN OF DEATH

Marcus A. Horwitz, M.D.
University of California School of Medicine

10:25 a.m.

QUESTIONS AND ANSWERS

10:30 a.m.

COFFEE BREAK

SYMPOSIUM 1:

INDUCTION OF SUSTAINED IMMUNE RESPONSES: ROLE OF IMMUNOLOGICAL MEMORY

CME

International A/B/C

Moderators: Diane E. Griffin, M.D., Ph.D.
Johns Hopkins Bloomberg School of Public Health
Paul-Henri Lambert, M.D.
Centre Medical Universitaire de Genève

Fifth Annual Conference

FINAL PROGRAM

- 11:00 a.m. **3. T-CELL MEMORY**
Rafi Ahmed, Ph.D.
Emory University School of Medicine
- 11:15 a.m. QUESTIONS AND ANSWERS
- 11:20 a.m. **4. B-CELL MEMORY AND THE PERSISTENCE OF ANTIBODY RESPONSES**
Ian C.M. MacLennan, M.B., Ph.D., FRCPath, FRCP
University of Birmingham School of Medicine, United Kingdom
- 11:35 a.m. Questions and Answers
- 11:40 a.m. **5. ROLE OF MEMORY IN VACCINE INDUCED PROTECTION**
Claire-Anne Siegrist, M.D., P.D.
University of Geneva
- 11:55 a.m. QUESTIONS AND ANSWERS
- 12:00 p.m. **6. MEMORY AT THE MUCOSAL LEVEL**
Myron M. Levine, M.D., D.T.P.H.
University of Maryland School of Medicine
- 12:15 p.m. QUESTIONS AND ANSWERS
- 12:20 p.m. LUNCH

SUBMITTED

PRESENTATIONS 1:

(Concurrent Session)

ADVANCES IN DNA-BASED VACCINES **CME**

International A/B/C

Moderators: Harriet L. Robinson, Ph.D.
*Yerkes Regional Primate Research Center
Emory University*
Connie Schmaljohn, Ph.D.
U.S. Army Medical Research Institute of Infectious Diseases

- 1:45 p.m. **S1 A GENE-BASED VACCINE FORMULATION IS SAFE, IMMUNOGENIC AND PROTECTIVE AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) IN INFANT RHESUS MACAQUES**
K. McArthur-Vaughan¹, L. J. Gershwin²
¹*School of Veterinary Medicine, Department of Pathology, Microbiology and Immunology, University of California, Davis, CA*, ²*University of California, Davis, CA*
- 2:00 p.m. **S2 GENE GUN VACCINATION WITH A STRUCTURAL GENE OF HEPATITIS E VIRUS INDUCES PROTECTIVE IMMUNITY AGAINST HEPATITIS E VIRUS INFECTION IN CYNOMOLGUS MACAQUES**
S. Kamili, J. Spelbring, R. Abubaker, D. Carson, K. Krawczynski
Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA

on Vaccine Research

FINAL PROGRAM

- 2:15 p.m. S3 **RECOMBINANT SV40 VACCINE DELIVERY VEHICLES ENCODING HIV-1 GP120 AND IL-12 ELICIT STRONG CELL-MEDIATED IMMUNE RESPONSES AGAINST GP120**
H. J. McKee¹, M. Vera², P. Fortes², D. S. Strayer¹
¹Pathology, Jefferson Medical College, Philadelphia, PA, ²University of Pamplona, Pamplona, SPAIN
- 2:30 p.m. S4 **DIRECT LINKAGE OF IMMUNOSTIMULATORY DNA TO A VARIETY OF PROTEINS DRAMATICALLY ENHANCES TH1 AND CTL RESPONSES**
D. Higgins, S. Tuck, R. Rodriguez, F. Haycock, R. Ng, B. Milley, P. Traquina, M. Basu, K. Patton, G. Van Nest
Dynavax Technologies Corporation, Berkeley, CA
- 2:45 p.m. S5 **PREDOMINANCE OF IGG1 AGAINST HEPATITIS C BY A COMBINATION OF DNA PLASMID, CORE E1/E2 PROTEIN AND MOUNTANIDE**
M. Ghorbani¹, S. Aucoin¹, A. Giulivi², M. P. Carlos³, J. V. Torres³, D. E. Anderson³, F. J. Diaz-Mitoma¹
¹Children's Hospital of Eastern Ontario, Ottawa, ON, CANADA, ²Health Canada, Ottawa, ON, CANADA, ³University of California at Davis, Davis, CA
- 3:00 p.m. S6 **ENHANCED PLASMID VACCINE IMMUNE POTENCY THROUGH ENGINEERING NOVEL COSTIMULATORY MOLECULES**
D. B. Weiner¹, M. Chattergoo², M. Adadjanian³, M. J. Holterman⁴, M. B. Kutzler⁵, J. Eldridge⁵, Z. Israel⁵, J. J. Kim¹, J. Boyer⁶, G. Pavlakis⁶, R. Sekaly⁷
¹Pathology, University of Pennsylvania, Philadelphia, PA, ²Department of Pathology Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, ³IMM, Los Angeles, CA, ⁴CANVAC, University of Montreal, Montreal, PQ, ⁵Wyeth Vaccines, Pearl River, NY, ⁶NCI-FCRF, Fredrick, MD, ⁷CANVAC, University of Montreal, Montreal, PQ, CANADA

3:15 p.m. COFFEE BREAK

SUBMITTED

PRESENTATIONS 2:

(Concurrent Session)

INHALED INFLUENZA VACCINES

CME

Liberty Ballroom

Moderators: Michel De Wilde, Ph.D.
Aventis Pasteur
Richard J. Duma, M.D., Ph.D.
Halifax Medical Center

- 1:45 p.m. S7 **SEQUENCE VARIATION IN THE INFLUENZA A VIRUS NUCLEOPROTEIN ASSOCIATED WITH ESCAPE FROM CYTOTOXIC T LYMPHOCYTES**
G. Rimmelzwaan, J. Boon, T. Voeten, R. Fouchier, A. Osterhaus
Virology, Erasmus University, Rotterdam, NETHERLANDS

Fifth Annual Conference

FINAL PROGRAM

- 2:00 p.m. S8 **INTRANASAL DELIVERY OF DRY-POWDER INFLUENZA VACCINE INDUCES MUCOSAL AND SYSTEMIC IMMUNE RESPONSES IN RATS**
J. Huang¹, T. Crowder², A. Hickey², J. Mikszta¹, V. Sullivan¹, J. Alarcon¹, L. Garcia-Contreras²
¹*BD Technologies, Durham, NC*, ²*University of North Carolina, Chapel Hill, NC*
- 2:15 p.m. S9 **NASAL PROTEOSOME-FLU VACCINES INDUCE ENHANCED SERUM AND MUCOSAL ANTIBODIES IN PREVIOUSLY INFECTED OR IMMUNIZED HOSTS**
D. Burt, T. Jones, P. Gupta, F. Allard, G. Lowell
ID Biomedical, Ville Saint-Laurent, PQ, CANADA
- 2:30 p.m. S10 **GENETIC STABILITY OF FLUMIST™, A LIVE ATTENUATED INFLUENZA VIRUS VACCINE, THROUGHOUT THE MANUFACTURING PROCESSES**
C. Yang¹, J. Zhao¹, D. Ye¹, D. Buonagurio², G. D'Arco², Y. Kazachkov², A. Hu², M. Sidhu², T. Zamb², K. Coelingh¹, R. Spaete¹
¹*Aviron, Mountain View, CA*, ²*Wyeth Lederle Vaccines, Pearl River, NY*
- 2:45 p.m. S11 **INDIRECT EFFECTIVENESS (HERD IMMUNITY) FROM INTRANASAL COLD-ADAPTED, INFLUENZA VACCINE-TRIVALENT (CAIV-T) GIVEN TO CHILDREN 1.5 TO 18 YEARS OF AGE, 1998-2001**
P. A. Piedra¹, M. J. Gaglani², C. Kozinetz³, W. P. Glezen¹
¹*Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX*,
²*Pediatrics, Scott and White Clinics, Temple, TX*, ³*Pediatrics, Baylor College of Medicine, Houston, TX*
- 3:00 p.m. S12 **LARGE SCALE SAFETY STUDY OF FLUMIST IN 9,689 CHILDREN 1-17 YEARS OF AGE**
S. Black¹, H. Shinefield¹, J. Hansen¹, E. Lewis¹, K. Ensor¹, J. Johnson¹, R. Walker², C. Hessel², L. Bobleter², P. Mendelman²
¹*Vaccine Study Center, Kaiser Permanente of Northern California, Oakland, CA*,
²*Aviron, Mountain View, CA*

3:15 p.m. COFFEE BREAK

SYMPOSIUM 2:

AIDS VACCINES – BASIC SCIENCE PROMISE, CLINICAL RESEARCH PROGRESS

International A/B/C

Moderators: Harriet L. Robinson, Ph.D.
*Yerkes Regional Primate Research Center
Emory University*
Bruce G. Weniger, M.D.
Centers for Disease Control and Prevention

- 3:45 p.m. 7. **NEW DESIGNS FOR HIV VACCINES: ANTIGENS OF PROMISE FOR CTL AND BROADLY NEUTRALIZING ANTIBODIES**
Gary J. Nabel, M.D., Ph.D.
National Institutes of Health

on Vaccine Research

FINAL PROGRAM

- 4:10 p.m. QUESTIONS AND ANSWERS
- 4:15 p.m. 8. **RECENT PRIMATE TRIALS – CLEAR FORKS IN THE PATH TOWARDS AN AIDS VACCINE**
Harriet L. Robinson, Ph.D.
Emory University School of Medicine
- 4:40 p.m. QUESTIONS AND ANSWERS
- 4:45 p.m. **EFFICACY TRIALS: UPDATE THEIR STATUS AND WHAT HAPPENS WHEN ONE WORKS? (Panel Discussion)**
José G. Esparza, M.D., Ph.D.
(Panel Chair)
World Health Organization
- Donald P. Francis, M.D., D.Sc.
VaxGen, Inc.
- Lawrence Corey, M.D.
Fred Hutchinson Cancer Research Center
University of Washington
- Timothy D. Mastro, M.D.
Centers for Disease Control and Prevention
- Colonel Deborah L. Birx, M.D.
Walter Reed Army Institute of Research
- Paulo R. Teixeira, M.P.H.
Brazilian Ministry of Health
- Patricia Fast, M.D., Ph.D.
International AIDS Vaccine Initiative
- 5:20 p.m. DISCUSSION, QUESTIONS AND ANSWERS (PANEL)
- 5:50 p.m. ADJOURNMENT
- 6:00 p.m. EXHIBIT RECEPTION
- International D/E*

Fifth Annual Conference

FINAL PROGRAM

TUESDAY, MAY 7, 2002

7:00-8:00 a.m. REGISTRATION *International Foyer*

7:30 a.m. CONTINENTAL BREAKFAST/POSTER SET-UP (P1-P18) *International D/E*

SYMPOSIUM 3: **ECONOMICALLY IMPORTANT DISEASES OF FOOD ANIMALS** **CME** *International A/B/C*

Moderators: Brian W.J. Mahy, Ph.D., Sc.D., D.Sc.
Centers for Disease Control and Prevention
David E. Swayne, D.V.M., Ph.D.
U.S. Department of Agriculture

8:00 a.m. 9. **THE FOOT-AND-MOUTH DISEASE EPIDEMIC IN THE UNITED KINGDOM, 2001:
WHY VACCINATION WAS NOT EMPLOYED**
Alex I. Donaldson, MA, MVB, Ph.D., Sc.D., MRCVS
BBSRC Institute for Animal Health

8:15 a.m. QUESTIONS AND ANSWERS

8:20 a.m. 10. **NOVEL STRATEGIES TO CONTROL FOOT-AND-MOUTH DISEASE**
Marvin J. Grubman, Ph.D.
U.S. Department of Agriculture

8:35 a.m. QUESTIONS AND ANSWERS

8:40 a.m. 11. **VACCINATION AGAINST RESPIRATORY DISEASES OF POULTRY:
AVIAN INFLUENZA AND NEWCASTLE DISEASE**
David E. Swayne, D.V.M., M.Sc., Ph.D.
U.S. Department of Agriculture

8:55 a.m. QUESTIONS AND ANSWERS

9:00 a.m. 12. **VACCINATION OF POULTRY: THE SPECIAL CASE OF MAREK'S DISEASE –
HERPESVIRUS-INDUCED LYMPHOMAS**
Richard L. Witter, D.V.M., Ph.D.
U.S. Department of Agriculture

9:15 a.m. QUESTIONS AND ANSWERS

9:20 a.m. 13. **CONTROL OF BOVINE HERPESVIRUS DISEASES**
Lorne A. Babiuk, Ph.D.
University of Saskatchewan

on Vaccine Research

FINAL PROGRAM

9:35 a.m.

QUESTIONS AND ANSWERS

SUBMITTED

PRESENTATIONS 3:

(Concurrent Session)

RESPONSES TO FUSION PROTEINS AND FUSED GENES

International A/B/C

Moderators: Paul-Henri Lambert, M.D.
Centre Medical Universitaire de Genève
Gary J. Nabel, M.D., Ph.D.
National Institutes of Health

9:45 a.m.

S13 MYCOBACTERIAL HEAT SHOCK PROTEIN (HSP) FUSIONS: A NOVEL CLASS OF IMMUNOTHERAPEUTICS FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS (HPV) INFECTION

N. R. Chu¹, B. Wu¹, H. Liu¹, J. Wisniewski¹, A. Recktenwald¹, G. Rowse¹, H. A. Boux¹, L. Boux², L. Mizzen¹, M. I. Siegel²
¹*Stressgen Biotechnologies, Victoria, BC, CANADA*, ²*Stressgen Biotechnologies, Collegeville, PA*

10:00 a.m.

S14 ENHANCING MHC CLASS I ANTIGEN PRESENTATION BY TARGETING ANTIGEN TO CENTROSOMES
C. C. Hung

Pathology, Johns Hopkins University, Baltimore, MD

10:15 a.m.

**S15 HLA-A2 AND H-2Db-RESTRICTED CTL ACTIVITY INDUCED BY SGN-00101—
A FUSION PROTEIN COMPRISED OF HEAT SHOCK PROTEIN AND HUMAN PAPILLOMAVIRUS E7**

H. Liu¹, G. Rowse¹, N. R. Chu¹, B. Wu¹, H. A. Boux¹, M. I. Siegel²
¹*Stressgen Biotechnologies, Victoria, BC, CANADA*, ²*Stressgen Biotechnologies, Collegeville, PA*

10:30 a.m.

COFFEE BREAK

11:00 a.m.

S16 INDUCTION OF HBcAg-SPECIFIC CTL RESPONSES BY A HEAT SHOCK PROTEIN FUSED TO THE CORE ANTIGEN OF THE HEPATITIS B VIRUS

L. S. D. Anthony¹, H. Liu¹, G. Rowse¹, B. Wu¹, A. Recktenwald¹, L. A. Mizzen¹, H. Boux¹, M. I. Siegel²
¹*Stressgen Biotechnologies, Victoria, BC, CANADA*, ²*Stressgen Biotechnologies, Collegeville, PA*

11:15 a.m.

S17 ENHANCED IMMUNOGENICITY OF PNEUMOCOCCAL SURFACE ADHESIN A BY GENETIC FUSION TO CYTOKINES AND EVALUATION OF PROTECTIVE IMMUNITY IN MICE

D. O. Gor, X. Ding, Q. Li, M. Dubinsky, N. S. Greenspan
Institute of Pathology, Case Western Reserve University, Cleveland, OH

11:30 a.m.

S18 IMMUNIZATION OF MICE WITH A RECOMBINANT PROTEIN AND IMMUNOSTIMULATORY OLIGONUCLEOTIDES IS PROTECTIVE IN COCCIDIOIDOMYCOSIS

T. N. Kirkland, III
Pathology and Medicine, Univ. Calif., San Diego, San Diego, CA

Fifth Annual Conference

FINAL PROGRAM

- 11:45 a.m. S19 **CYTOKINE RESPONSE TO COCCIDIOIDES IMMITIS INFECTION IN C57BL/6 MICE**
J. Xue, C. Hung, G. T. Cole
Microbiology and Immunology, Medical College of Ohio, Toledo, OH
- 12:00 p.m. S20 **A GALACTOSE/GALACTOSAMINE BINDING LECTIN AS A MUCOSAL ADJUVANT/CARRIER FOR PLANT-BASED VACCINES**
F. Medina-Bolivar¹, V. Funk¹, R. Wright¹, D. Sentz¹, T. D. Wilkins¹, W. Petri, Jr.², C. L. Cramer¹
¹*Fralin Biotechnology Center, Virginia Tech, Blacksburg, VA*, ²*Department of Medicine, University of Virginia Health System, Charlottesville, VA*
- 12:15 p.m. Lunch

SUBMITTED

PRESENTATIONS 4:

(Concurrent Session)

CLINICAL STUDIES

CME

Liberty Ballroom

Moderators: William J. Martone, M.D.
National Foundation for Infectious Diseases
Bruce G. Weniger, M.D.
Centers for Disease Control and Prevention

- 9:45 a.m. S21 **A PHASE I TRIAL FOR THE TREATMENT OF HPV+ AIN WITH A MICROPARTICLE PLASMID DNA VACCINE (ZYC101)**
M. Matijevic¹, B. Klencke², J. Lathey¹, M. L. Hedley¹, J. Palefsky³, R. G. Urban¹
¹*ZYCOS Inc., Lexington, MA*, ²*Cancer Center, University of California at San Francisco, San Francisco, CA*, ³*University of California at San Francisco, San Francisco, CA*
- 10:00 a.m. S22 **A PHASE I STUDY OF THE WRAIR TETRAVALENT LIVE ATTENUATED DENGUE VACCINE IN FLAVIVIRUS-IMMUNE ADULT VOLUNTEERS**
N. Kanesa-thasan, L. Hernandez, A. Lyons, R. Putnak, W. Sun, D. McKinney, D. Vaughn
Walter Reed Army Institute of Research, Silver Spring, MD
- 10:15 a.m. S23 **ALVAC-HIV (vCP1521) PRIMING WITH AIDSVAX B/E BOOSTING IN THAILAND: SAFETY AND IMMUNOGENICITY RESULTS**
P. Pitisuttithum¹, S. Nitayaphan², J. Kim³, V. Polonis³, S. Ratto-Kim³, W. Heyward⁴, S. Gurunathan⁵, M. de Souza², A. Brown and TAVEG²
¹*Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Bangkok, THAILAND*, ²*AFRIMS, Bangkok, THAILAND*, ³*WRAIR, Rockville, MD*, ⁴*VaxGen, Brisbane, CA*, ⁵*Aventis Pasteur, Swiftwater, PA*
- 10:30 a.m. COFFEE BREAK *International D/E*

on Vaccine Research

FINAL PROGRAM

- 11:00 a.m. S24 **HIGH DOSE HEPATITIS B VACCINE IN LUNG TRANSPLANT PATIENTS**
M. S. Hayney, D. L. Welter, A. Reynolds, R. L. Love
University of Wisconsin, Madison, WI
- 11:15 a.m. S25 **CHARACTERIZATION OF THE EFFICACY AND THE IMMUNE RESPONSE OF NABI® STAPHVAX™ (A BIVALENT STAPHYLOCOCCUS AUREUS (S. AUREUS) TYPE 5 AND TYPE 8 CAPSULAR POLYSACCHARIDE (CP) CONJUGATE VACCINE) IN HEMODIALYSIS PATIENTS**
A. I. Fattom, Y. Wu, M. Propst, S. Fuller, G. Horwith, R. Naso
Research, Nabi, Rockville, MD
- 11:30 a.m. S26 **SAFETY AND IMMUNOGENICITY OF 26-VALENT GROUP A STREPTOCOCCUS (GRAS) VACCINE IN HEALTHY ADULTS**
S. McNeil¹, S. Halperin¹, J. M. Langley¹, M. Reddish², M. C. H. Hu², S. Stroop², M. Walls², J. Linden², G. Lowell², L. Fries², J. Dale³
¹Dalhousie University, Halifax, NS, CANADA, ²ID Biomedical Corp., Bothell, WA, ³VA Medical Center & Univ. Tennessee, Memphis, TN
- 11:45 a.m. S27 **QS-21 Enhances the Response to Pneumococcal Conjugate Vaccine in the Elderly**
J. J. Treanor¹, C. Nolan¹, C. Anderson², C. R. Kensil²
¹Infectious Diseases Unit, University of Rochester, Rochester, NY, ²Antigenics Inc, Framingham, MA
- 12:00 p.m. S28 **TWO PAEDIATRIC DOSES OF TWINRIX OR RECOMBIVAX PROVIDES NEARLY AS GOOD PROTECTION AS THREE DOSES TO PRE-TEENAGERS**
B. Duval¹, N. Boulianne¹, G. De Serres¹, G. Deceuninck²
¹Institut National de Santé Publique du Québec, Beauport, PQ, CANADA, ²Centre de recherche du Centre Hospitalier Universitaire du Québec, Québec, Canada, Beauport, PQ, CANADA
- 12:15 p.m. LUNCH
- SUBMITTED PRESENTATIONS 5:** **BIOINFORMATICS AND VACCINOLOGY** **CME** *Liberty Ballroom*
(Concurrent Session) Moderators: David A. Neumann, Ph.D.
National Foundation for Infectious Diseases
Kathryn C. Zoon, Ph.D.
U.S. Food and Drug Administration
- 1:30 p.m. S29 **BUILDING VACCINES FROM IMMUNOGENIC CONSENSUS SEQUENCES**
A. S. De Groot¹, R. G. Scheib², K. McGowen³, D. Doughty⁴, A. Bosma⁵, W. Martin⁵
¹EpiVax, Inc., Providence, RI, ²Shattuck Hospital, Boston, MA, ³Faulkner Hospital, Jamaica Plain, MA, ⁴TB/HIV Research Lab, Brown University, Providence, RI, ⁵EpiVax, Providence, RI

Fifth Annual Conference

FINAL PROGRAM

- 1:45 p.m. S30 **PROFILING GENE EXPRESSION CHANGES ASSOCIATED WITH EIMERIA INFECTIONS USING HIGH-THROUGHPUT cDNA MICROARRAYS**
W. S. Min¹, H. S. Lillehoj¹, S. Kim¹, H. Beard², N. Alkharouf², B. F. Matthews².
¹*Animal and Natural Resources Institute, United States Department of Agriculture, Beltsville, MD*, ²*Soybean and Alfalfa Research Laboratory, United States Department of Agriculture, Beltsville, MD*
- 2:00 p.m. S31 **THE ROLE OF HLA GENES IN MEASLES VACCINE VIRUS (MVV) ANTIBODY (Ab) HYPER-RESPONSE**
I. G. Ovsyannikova, R. M. Jacobson, R. A. Vierkant, D. J. Schaid, S. J. Jacobsen, G. A. Poland
Mayo Vaccine Research Group, Mayo Clinic and Foundation, Rochester, MN
- 2:15 p.m. S32 **DIFFERENTIAL HLA GENE EXPRESSION IN RESPONDERS AND NON-RESPONDERS TO MEASLES VACCINE VIRUS (MVV) USING GENECHIP EXPRESSION ARRAYS**
N. Dhiman, R. B. Guerrero, R. M. Jacobson, D. J. O’Kane, G. A. Poland
Mayo Vaccine Research Group, Mayo Clinic and Foundation, Rochester, MN
- 2:30 p.m. S33 **CYTOKINE mRNA EXPRESSION PROFILE AFTER MEASLES VACCINE VIRUS IMMUNIZATION FAILURE**
R. Bonilla Guerrero¹, N. Dhiman¹, R. M. Jacobson², D. J. O’Kane³, G. A. Poland¹
¹*Vaccine Research Group, Mayo Clinic, Rochester, MN*, ²*Vaccine Research, Mayo Clinic, Rochester, MN*, ³*Cancer Center Microarray and Molecular Epidemiology, Mayo Clinic, Rochester, MN*
- 3:00 p.m. COFFEE BREAK *International D/E*
- SYMPOSIUM 4:** **BASIC IMMUNOLOGY FOR VACCINE DEVELOPMENT** **CME** *International A/B/C*
(Concurrent Session) Moderators: Stanley A. Plotkin, M.D.
Aventis Pasteur/University of Pennsylvania
Ethan M. Shevach, M.D.
National Institutes of Health
- 1:30 p.m. 14. **ROLE OF CpG MOTIFS IN DNA VACCINES**
Heather L. Davis, Ph.D.
Coley Pharmaceutical Group
- 1:45 p.m. QUESTIONS AND ANSWERS
- 1:50 p.m. 15. **ANTIGEN PRESENTATION BY CD1 MOLECULES**
Michael B. Brenner, M.D.
Harvard Medical School
- 2:05 p.m. QUESTIONS AND ANSWERS

on Vaccine Research

FINAL PROGRAM

2:10 p.m. 16. **THE ROLE OF TOLL-LIKE RECEPTORS IN ORCHESTRATING THE INNATE IMMUNE RESPONSE**
Alan Aderem, Ph.D.
Institute for Systems Biology

2:25 p.m. QUESTIONS AND ANSWERS

2:30 p.m. 17. **HEAT SHOCK PROTEINS AS ADJUVANTS**
Sreyashi Basu, Ph.D.
University of Connecticut School of Medicine

2:45 p.m. QUESTIONS AND ANSWERS

2:50 p.m. COFFEE BREAK

International D/E

SYMPOSIUM 5:

THE GLOBAL ALLIANCE FOR VACCINES AND IMMUNIZATION – RESEARCH & DEVELOPMENT AGENDA

CME

International A/B/C

Moderators: Myron M. Levine, M.D., D.T.P.H.
University of Maryland School of Medicine
Bruce G. Weniger, M.D.
Centers for Disease Control and Prevention

3:30 p.m. 18. **OVERVIEW OF THE RESEARCH AND DEVELOPMENT ACTIVITIES OF THE GLOBAL ALLIANCE FOR VACCINES AND IMMUNIZATION**
Myron M. Levine, M.D., D.T.P.H.
University of Maryland School of Medicine

3:45 p.m. QUESTIONS AND ANSWERS

3:50 p.m. 19. **ROTAVIRUS VACCINE DEVELOPMENT BY THE GLOBAL ALLIANCE FOR VACCINES AND IMMUNIZATION**
Roger I. Glass, M.D., Ph.D.
Centers for Disease Control and Prevention

4:05 p.m. QUESTIONS AND ANSWERS

4:10 p.m. 20. **THE GAVI PNEUMOCOCCAL VACCINE ACCELERATED DEVELOPMENT AND INTRODUCTION PLAN**
Orin S. Levine, Ph.D.
National Institutes of Health

4:25 p.m. QUESTIONS AND ANSWERS

4:30 p.m. 21. **THE MENINGITIS VACCINE PROJECT: A PARTNERSHIP BETWEEN WHO AND PATH**
F. Marc LaForce, M.D.
Program for Appropriate Technology and Health (PATH) – Europe

Fifth Annual Conference

FINAL PROGRAM

- 4:45 p.m. 22. **VACCINE TECHNOLOGY DEVELOPMENTS BY THE GLOBAL ALLIANCE FOR VACCINES AND IMMUNIZATION**
Gordon Dougan, D.Phil
Imperial College of Science, Technology & Medicine
- 5:05 p.m. QUESTIONS AND ANSWERS
- 5:10 p.m. PANEL DISCUSSION
- 5:45 p.m. ADJOURNMENT
- 6:30 p.m. RECEPTION *Liberty Ballroom*
- 7:30 p.m. PRESENTATION OF THE ALBERT B. SABIN GOLD MEDAL *International A/B/C*

WEDNESDAY, MAY 8, 2002

- 7:00-8:00 a.m. REGISTRATION *International Foyer*
- 7:30 a.m. CONTINENTAL BREAKFAST/POSTER SET-UP (P19-42) *International D/E*

SYMPOSIUM 6:

HUMAN PAPILLOMAVIRUS

CME

International A/B/C

Moderators: Diane E. Griffin, M.D., Ph.D.
Johns Hopkins Bloomberg School of Public Health
Gary J. Nabel, M.D., Ph.D.
National Institutes of Health

- 8:00 a.m. 23. **PATHOGENESIS OF HPV-ASSOCIATED CANCER**
Keerti V. Shah, M.D. Dr.P.H.
Johns Hopkins Bloomberg School of Public Health
- 8:15 a.m. QUESTIONS AND ANSWERS
- 8:20 a.m. 24. **ENDPOINTS FOR PREVENTIVE HUMAN PAPILLOMAVIRUS (HPV) VACCINE EFFICACY TRIALS**
R. Douglas Pratt, M.D., M.P.H.
U.S. Food and Drug Administration
- 8:35 a.m. QUESTIONS AND ANSWERS
- 8:40 a.m. 25. **TRIALS OF PREVENTIVE VACCINES**
John T. Schiller, Ph.D.
National Institutes of Health

on Vaccine Research

FINAL PROGRAM

8:55 a.m. QUESTIONS AND ANSWERS

9:00 a.m. 26. **STATUS OF PROPHYLACTIC VACCINES AGAINST CERVICAL CANCER**
Kathrin U. Jansen, Ph.D.
Merck & Co., Inc.

9:15 a.m. QUESTIONS AND ANSWERS

9:20 a.m. 27. **CURRENT STATUS OF THERAPEUTIC VACCINES**
Drew Pardoll, M.D., Ph.D.
Johns Hopkins University School of Medicine

9:35 a.m. QUESTIONS AND ANSWERS

SUBMITTED

PRESENTATIONS 6:

(Concurrent Session)

ANTIGENS AND ENHANCING ANTIGENICITY



International A/B/C

Moderators: Peter L. Nara, D.V.M., Ph.D.
Biological Mimetics, Inc.
David A. Newmann, Ph.D.
National Foundation for Infectious Diseases

9:45 a.m. S34 **IMPROVED BIOLOGICAL ACTIVITIES FOR NOVEL HIV-1 ENVELOPE VACCINE CANDIDATES GENERATED BY DNA SHUFFLING.**
L. Xu¹, X. Du¹, W. Zhang¹, D. R. Burton², P. W. H. I. Parren³, R. G. Whalen¹
¹*Maxygen, Inc., Redwood City, CA*, ²*The Scripps Research Institute, La Jolla, CA*,
³*Genmab, Utrecht, NETHERLANDS*

10:00 a.m. S35 **NEW USES FOR LICENSED VACCINES: EVALUATION OF THE JAPANESE ENCEPHALITIS VIRUS VACCINE AND THE NY99 WEST NILE VIRUS GENOMES FOR CROSS-REACTIVE T CELL EPITOPES**
A.S. De Groot¹, A. Bosma², C. Saint Aubin¹, H. Sbai¹, W. Martin²
¹*TB/HIV Research Laboratory, Brown University, Providence, RI*, ²*EpiVax, Inc., Providence, RI*

10:15 a.m. S36 **ANALYZING MYCOBACTERIUM TUBERCULOSIS PROTEOMES FOR CANDIDATE TB VACCINE EPITOPES**
A.S. De Groot¹, H. Sbai², J. A. McMurry², M. L. Gennaro³, E. J. Carter⁴,
W. Martin⁵
¹*EpiVax, Inc., Providence, RI*, ²*TB/HIV Research Lab, Brown University, Providence, RI*,
³*Public Health Research Institute, New York City, NY*, ⁴*Brown University, Providence, RI*,
⁵*EpiVax, Providence, RI*

10:30 a.m. COFFEE BREAK

International D/E

Fifth Annual Conference

FINAL PROGRAM

- 11:00 a.m. **S37 ADDITION OF CpG-CONTAINING OLIGONUCLEOTIDES TO A HEPATITIS B VACCINE MARKEDLY ENHANCES THE ANTIBODY AVIDITY MATURATION PROCESS IN HEALTHY ADULTS**
C. A. Siegrist¹, M. Pihlgren¹, C. Tougne¹, S. M. Elfer², M. Morris², W. Cameron³,
C. Cooper³, J. Heathcote⁴, H. L. Davis², P. H. Lambert¹
¹Center for Neonatal Vaccinology, University of Geneva, SWITZERLAND,
²Coley Pharmaceutical Group, Ottawa, ON, CANADA, ³The Ottawa Hospital,
Ottawa, ON, CANADA, ⁴The Toronto Hospital, Toronto, ON, CANADA
- 11:15 a.m. **S38 QS-21 STRUCTURE/FUNCTION STUDIES: EFFECT OF ACRYLATION ON ADJUVANT ACTIVITY**
G. Liu¹, C. Anderson², C. Kensil²
¹Antigenics Inc., Framingham, MA, ²Antigenics, Framingham, MA
- 11:30 a.m. **S39 NOVEL ADJUVANT FORMULATIONS CONTAINING A THERMAL-SETTING BLOCK COPOLYMER AND SELECTED IMMUNOMODULATORS ELICIT POTENT AND LONG LASTING ANTIBODY RESPONSES IN MICE**
C. M. Coeshott, E. Verderber, A. Samaniego, G. J. Rosenthal;
RxKinetix Inc., Louisville, CO
- 11:45 a.m. **S40 TRANSDERMAL IMMUNOGENICITY OF HUMAN PAPILLOMAVIRUS-LIKE PARTICLES ADMINISTERED IN COMBINATION WITH E. COLI LT(R192G)**
J. DiNapoli¹, C. Lane¹, J. D. Clements², R. C. Rose¹
¹University of Rochester Medical Center, Rochester, NY, ²Tulane University Health
Sciences Center, New Orleans, LA
- 12:00 p.m. **S41 RECOMBINANT SV40 VECTORS ENCODING HIV-1 GP120 AND IL-15 ELICIT DURABLE IMMUNE RESPONSES AGAINST GP120**
H. J. McKee¹, M. Vera², P. Fortes², D. S. Strayer¹
¹Pathology, Jefferson Medical College, Philadelphia, PA, ²University of Pamplona,
Pamplona, SPAIN.
- 12:15 p.m. LUNCH

SUBMITTED

PRESENTATIONS 7:

(Concurrent Session)

OCULO-RESPIRATORY SYNDROME AND INFLUENZA VACCINE



Liberty Ballroom

Moderators: Richard J. Duma, M.D., Ph.D.


Halifax Medical Center

William J. Martone, M.D.

National Foundation for Infectious Diseases

on Vaccine Research

FINAL PROGRAM

- 9:45 a.m. S42 **OCULO-RESPIRATORY SYNDROME FOLLOWING INFLUENZA VACCINE: RECURRENCE RISK WITH RE-FORMULATED VACCINE FOR 2001-2002**
D. M. Skowronski¹, G. De Serres², R. Warrington³, M. L. Russell⁴, D. Davies⁴, B. Duval², M. Dionne², G. Hammond³, J. Kellner⁴, B. Law³, J. MacDonald⁴, D. Scheifele¹
¹University of British Columbia, Vancouver, BC, CANADA, ²Centre de Sante Publique, Beauport, PQ, CANADA, ³Health Sciences Center, Winnipeg, MB, CANADA, ⁴University of Calgary, Calgary, AB, CANADA
- 10:00 a.m. S43 **OCULO-RESPIRATORY SYNDROME (ORS) AMONG HEALTHY ADULTS GIVEN A REFORMULATED INFLUENZA VACCINE PREVIOUSLY LINKED WITH ORS**
D. W. Scheifele, B. Duval, M. Russell, R. Warrington, G. De Serres, M. Dionne, D. Skowronski, D. Davies, J. Kellner, J. MacDonald
Canadian Association for Immunization Research and Evaluation (CAIRE), Vancouver, BC, CANADA
- 10:15 a.m. S44 **OCULO-RESPIRATORY SYNDROME AFTER INFLUENZA VACCINATION: SIMILAR RISK WITH TWO 2001-2002 INFLUENZA VACCINES**
G. De Serres¹, N. Boulianne¹, B. Duval¹, L. Rochette¹, & Groupe central ESPRI²
¹INSPQ, Quebec, PQ, CANADA, ²Quebec Public health network, Quebec, PQ, CANADA
- 10:30 a.m. COFFEE BREAK International D/E
- SUBMITTED PRESENTATIONS 8:** **VACCINE DESIGN AND DEVELOPMENT**  Liberty Ballroom
(Concurrent session) Moderators: Harriet L. Robinson, Ph.D.
Yerkes Regional Primate Research Center
Emory University
Connie Schmaljohn, Ph.D.
U.S. Army Medical Research Institute of Infectious Diseases
- 11:00 a.m. S45 **ORAL IMMUNOGENICITY OF HUMAN PAPILLOMAVIRUS VIRUS-LIKE PARTICLES EXPRESSED IN POTATO**
H. Warzecha¹, H. Mason¹, C. Arntzen², J. D. Clements³, C. Lane⁴, R. C. Rose⁴
¹Boyce Thompson Institute for Plant Research, Ithaca, NY, ²Arizona State University, Tempe, AZ, ³Tulane University Health Sciences Center, New Orleans, LA, ⁴University of Rochester Medical Center, Rochester, NY
- 11:15 a.m. S46 **A NEW SUBUNIT VACCINE FOR TUBERCULOSIS CONTAINING THE DISSEMINATION FACTOR, HBHA**
T. E. Pickett¹, M. Parra¹, K. Pethe², F. D. Menozzi², C. Lochter², M. J. Brennan¹
¹FDA, Bethesda, MD, ²Institut Pasteur de Lille, Lille, FRANCE

Fifth Annual Conference

FINAL PROGRAM

- 11:30 a.m. S47 **COMPLETELY STABLE LIQUID VACCINES**
B. J. Roser, S. D. Sen
School of Applied Sciences, Cambridge Biostability Ltd, APU, Cambridge, UNITED KINGDOM
- 11:45 a.m. S48 **IMMUNOGENICITY AND EFFICACY OF A NOVEL SHIGELLA INVASIN COMPLEX ETEC COLONIZATION FACTOR BIVALENT VACCINE IN MICE**
E. V. Oaks, K. R. Turbyfill, W. A. Byrd, F. J. Cassels
Enteric Infections/ DCD&I, Walter Reed Army Institute of Research, Silver Spring, MD
- 12:00 p.m. S49 **PHASE III EFFICACY TRIALS OF LPS SHIGELLA SONNEI VACCINE: SEASONAL PROTECTION AGAINST SHIGELLOSIS SONNEI IN MID-VOLGA REGION**
P. G. Aparin¹, L. L. Pavlova², M. A. Gorbunov², T. V. Gantcho³, M. E. Golovina¹, R. P. Chuprinina², T. I. Nemirovskya², R. S. Rachmanov³, V. I. Ershov³, E. B. Kurenkova⁴, I. A. Prochnitskaya⁴, I. V. Ankudinov¹, S. I. Yolkina³, V. L. L'vov¹
¹NRC-Institute of Immunology, Moscow, RUSSIAN FEDERATION, ²National Institute Biological Standartization MOH, Moscow, RUSSIAN FEDERATION, ³ATV D-TEAM Co.,Ltd, Moscow, RUSSIAN FEDERATION, ⁴Saratov regional MOH, Saratov, RUSSIAN FEDERATION
- 12:15 p.m. LUNCH

SYMPOSIUM 7:

NEW VACCINE TECHNOLOGIES **CME**

International A/B/C

Moderators: N. Regina Rabinovich, M.D.
Program for Appropriate Technology in Health
Harriet L. Robinson, Ph.D.
Yerkes Regional Primate Research Center
Emory University

- 1:30 p.m. 28. **BREEDING NEW VACCINES**
Russell J. Howard, Ph.D.
Maxygen, Inc.
- 1:45 p.m. QUESTIONS AND ANSWERS
- 1:50 p.m. 29. **A NOVEL VIRAL VECTOR FOR VACCINATION**
Hildegund C. J. Ertl, M.D.
Wistar Institute
- 2:05 p.m. QUESTIONS AND ANSWERS

on Vaccine Research

FINAL PROGRAM

- 2:10 p.m. 30. **VACCINE DEVELOPMENT IN TRANSGENIC ANIMALS**
Harry M. Meade, M.D.
Genzyme Transgenic
- 2:25 p.m. QUESTIONS AND ANSWERS
- 2:30 p.m. 31. **REGULATORY ISSUES FOR NEW VACCINE TECHNOLOGIES**
Lieutenant Commander Jon R. Daugherty, Ph.D., U.S.P.H.S.
U.S. Food and Drug Administration
- 2:45 p.m. QUESTIONS AND ANSWERS
- 2:50 p.m. COFFEE BREAK *International D/E*
- SYMPOSIUM 8:** **PRACTICAL ISSUES IN CLINICAL TRIALS** **CME** *International A/B/C*
Moderators: N. Regina Rabinovich, M.D.
Program for Appropriate Technology in Health
Myron M. Levine, M.D., D.T.P.H.
University of Maryland School of Medicine
- 3:20 p.m. 32. **ASSESSING VACCINE SAFETY IN PRE-LICENSURE CLINICAL TRIALS: AN INDUSTRY PERSPECTIVE**
William C. Gruber, M.D.
Wyeth Vaccines
- 3:35 p.m. QUESTIONS AND ANSWERS
- 3:40 p.m. 33. **ASSESSING VACCINE SAFETY IN PRE-LICENSURE CLINICAL TRIALS: A REGULATORY PERSPECTIVE**
Karen Midthun, M.D.
U.S. Food and Drug Administration
- 3:55 p.m. QUESTIONS AND ANSWERS
- 4:00 p.m. 34. **VACCINE TRIALS AND THE ASSESSMENT OF HERD IMMUNITY**
Paul E.M. Fine, V.M.D., Ph.D.
London School of Hygiene and Tropical Medicine
- 4:15 p.m. QUESTIONS AND ANSWERS
- 4:20 p.m. 35. **CONTENTIOUS ETHICAL ISSUES IN PERFORMING CLINICAL VACCINE TRIALS IN DEVELOPING COUNTRIES: A BIOETHICAL PERSPECTIVE**
Charles Weijer, M.D., Ph.D.
Dalhousie University

Fifth Annual Conference

FINAL PROGRAM

- 4:35 p.m. QUESTIONS AND ANSWERS
- 4:40 p.m. PARTICIPANT EVALUATION
- 4:45 p.m. ADJOURNMENT

POSTER GROUP 1: DESIGNING AND ENHANCING VACCINES

- P1 BROAD SPECTRUM PULSED LIGHT-INACTIVATED HERPESVIRUS ANTIGEN PREPARATIONS FOR SEROLOGICAL ASSAYS AND POTENTIAL VIRUS VACCINES**
D. Katz¹, P. Krug¹, W. Shi¹, J. Hilliard¹, J. Holloway², W. Cover²
¹Viral Immunology Center, Georgia State University, Atlanta, GA, ²PureBright® Technologies, San Diego, CA
- P2 LIPOSOMAL gD VACCINE (LIPGD-HD) PROTECTS BALB/c AND C57BL/6 MALE MICE CHALLENGED INTRARECTALLY (IREC) WITH HERPES SIMPLEX VIRUS (HSV2)**
L. H. J. Song¹, R. Masoud¹, W. Ernst², G. Fujii², J. P. Adler-Moore¹
¹Biological Sciences, California State Polytechnic University, Pomona, Pomona, CA, ²Molecular Express Inc., Los Angeles, CA
- P3 WITHDRAWN**
- P4 ENHANCED ANTIBODY RESPONSE AND PROTECTIVE CAPACITY OF JAPANESE ENCEPHALITIS VIRUS DNA VACCINE WITH A COMBINATION OF PLASMIDS EXPRESSING ENVELOPE AND NONSTRUCTURAL PROTEIN GENES**
C. Pan¹, H. Chen², H. Huang³, H. Yen³, M. Tao³
¹Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, MD, ²National Health Research Institute, Taipei, TAIWAN REPUBLIC OF CHINA, ³Institution of Biomedical Sciences, Academia Sinica, Taipei, TAIWAN REPUBLIC OF CHINA
- P5 WITHDRAWN**
- P6 IMMUNOSTIMULATORY ACTIONS OF SGN-00101 AND THE SEPARATION OF THESE EFFECTS FROM LIPOPOLYSACCHARIDE**
G. Rowse¹, N. Chu¹, E. Wiebe¹, A. Recktenwald¹, L. Mizzen¹, H. Boux¹, M. I. Siegel²
¹Stressgen Biotechnologies, Victoria, BC, CANADA, ²Stressgen Biotechnologies, Collegeville, PA

on Vaccine Research

FINAL PROGRAM

- P7 THE NOVEL ADJUVANT OM-174 ACTIVATES MURINE BONE MARROW DENDRITIC CELLS THROUGH TLR-4 AND CAN ALSO SIGNAL THROUGH HUMAN TLR-2**
J. Samsom¹, G. Kraal¹, R. Lauener², C. Chiavaroli³, J. Bauer³, G. Davies³
¹*Department of Molecular Cell Biology, VUMC, Amsterdam, NETHERLANDS,*
²*Division of Immunology and Hematology, Kinderspital, Zurich, SWITZERLAND,*
³*OM PHARMA, Geneva, SWITZERLAND*
- P8 THE DEVELOPMENT OF TRANSGENIC PLANTS FOR PRODUCTION AND DELIVERY OF A MULTICOMPONENT TUBERCULOSIS VACCINE.**
M. M. Rigano¹, Y. Jin¹, J. Pinkhasov¹, D. D. Kirk², F. Sala³, C. J. Arntzen¹,
A. M. Walmsley¹
¹*Department of Plant Biology, Arizona State University, Tempe, AZ,*
²*Boyce Thompson Institute for Plant Research, Ithaca, NY,* ³*Department of Biology, University of Milan, Milan, ITALY*
- P9 A PLANT BASED BREAST CANCER VACCINE**
J. Pinkhasov¹, D. D. Kirk², P. Mukherjee³, S. J. Gendler³, C. J. Arntzen¹,
A. M. Walmsley¹
¹*Department of Plant Biology, Arizona State University, Tempe, AZ,* ²*Boyce Thompson Institute for Plant Research, Ithaca, NY,* ³*Department of Biochemistry and Molecular Biology & Tumor Biology Program, Mayo Clinic Scottsdale, Scottsdale, AZ*
- P10 EXPRESSION OF IMMUNOGENIC HANTAVIRAL PROTEINS IN TRANSGENIC TOBACCO (NICOTIANA TABACUM) AND POTATO (SOLANUM TUBEROSUM) PLANTS.**
A. Rösen-Wolff¹, S. Khattak², G. Darai³
¹*Pediatrics, Klinik und Poliklinik für Kinder- und Jugendmedizin TU Dresden, Dresden, GERMANY,* ²*Klinik und Poliklinik für Kinder- und Jugendmedizin, Technical University of Dresden, GERMANY,* ³*Institut für Medizinische Virologie, University of Heidelberg, GERMANY*
- P11 EXPRESSION OF AN SIV PROTEIN IN TRANSGENIC MAIZE FOR USE AS AN EDIBLE VACCINE AND REAGENT SUPPLY**
M. E. Horn¹, M. Bailey², R. C. Clough³, S. M. Souers⁴, J. M. Jilka⁴, S. L. Woodard²
¹*Cell Biology, ProdiGene, College Station, TX,* ²*Biochemistry, ProdiGene, College Station, TX,* ³*Molecular Biology, ProdiGene, College Station, TX,* ⁴*ProdiGene, College Station, TX*

POSTER GROUP 2: VETERINARY VACCINES

- P12 CpG DNA AND ITS USE IN FISH VACCINES**
A. C. Carrington¹, C. Secombes¹, T. Ellis², J. Jørgensen³
¹*Department of Zoology, University of Aberdeen, Aberdeen, UNITED KINGDOM,*
²*FRS. Marine Lab., Aberdeen, UNITED KINGDOM,* ³*Fiskeriforskning, Norwegian Institute of Fisheries and Aquaculture, Tromsø, NORWAY*

Fifth Annual Conference

FINAL PROGRAM

P13 AGE DIFFERENCE IN LYMPHOCYTE PROLIFERATION, AND IL-2 AND IFN-GAMMA PRODUCTION FOLLOWING SALMONELLA ENTERITIDIS VACCINATION

M. Okamura¹, H. S. Lillehoj¹, R. B. Raybourne², U. S. Babu², R. A. Heckert³
¹Ars, United States Department of Agriculture, Beltsville, MD, ²Immunology Branch, Center for Food Safety and Applied Nutrition, Food and Drug Administration, Laurel, MD, ³Department of Avian Diseases, University of Maryland, College Park, MD

P14 HIGH INCIDENCE OF COCCIDIODES IMMITIS SEROCONVERSION IN DOGS POINTS TO NEED FOR CANINE VACCINE TRIALS

L. Shubitz¹, J. Galgiani², R. F. Hector³, C. Lindan³, G. W. Rutherford³
¹University of Arizona, Tucson, AZ, ²Section of Infectious Diseases, University of Arizona, Tucson, AZ, ³Epidemiology & Biostatistics, UCSF, San Francisco, CA

P15 MYCOBACTERIUM BOVIS BCG VACCINATION OF CATTLE: ACTIVATION AND PROLIFERATION OF LYMPHOCYTE SUBSETS UPON STIMULATION WITH MYCOBACTERIAL ANTIGENS

W. R. Waters¹, B. J. Nonnecke¹, T. E. Rahner¹, M. V. Palmer¹, D. L. Whipple¹, M. R. Foote¹, A. C. Maue², D. M. Estes²
¹National Animal Disease Center, Ames, IA, ²University of Missouri, Columbia, MO

P16 HUMORAL RESPONSE OF NELORE CALVES AFTER APPLICATION OF AUTOVACCINES PREPARED FROM PSEUDOMONAS AERUGINOSA

O. J. Nolte¹, H. E. Weiss¹, C. Weiss¹, I. S. Dutra², H. G. Sonntag¹
¹Hygiene-Institut, Heidelberg, GERMANY, ²Unesp, Aracatuba-SP, BRAZIL

P17 WITHDRAWN

P18 ANTIBODY RESPONSE TO VACCINATION WITH INACTIVATED COWDRIA RUMINANTIIUM (GARDEL STRAIN) IN UGANDAN GOATS

M. M. K. Saimo
Veterinary Medicine, Makerere University, Kampala, UGANDA

POSTER GROUP 3: BASIC IMMUNOLOGY

P19 ROLE OF LANGERHANS CELLS IN EPIDERMAL POWDER IMMUNIZATION

D. Chen, Q. Chu, L. G. Payne
PowderJect Vaccines, Madison, WI

P20 AMINO ACID DIMORPHISM IN THE MEROZOITE SURFACE PROTEIN-1 OF PLASMODIUM FALCIPARUM AS IMMUNE EVASION MECHANISM

C. A. Daubenberger¹, B. Nickel¹, C. Ciatto², G. Pluschke¹
¹Molecular Immunology, Swiss Tropical Institute, Basel, SWITZERLAND,
²Institute of Biochemistry, University of Zuerich, Zuerich, SWITZERLAND

on Vaccine Research

FINAL PROGRAM

P21 **WITHDRAWN**

P22 **EVALUATION OF HIGH MOLECULAR WEIGHT POLYSACCHARIDE ADHESIN FROM STAPHYLOCOCCUS AUREUS**

J. Joyce¹, C. Abeygunawardana¹, Q. Xu¹, J. Cook¹, R. Hepler¹, C. Przysiecki¹,
K. Grimm¹, K. Roper¹, C. Ip¹, L. Cope¹, D. Montgomery¹, M. Chang¹, S. Campie¹,
G. B. Pier², G. Mark¹, P. Keller¹, K. Jansen¹

¹Merck Research Laboratories, West Point, PA, ²Harvard Medical School, Brigham and Women's Hospital, Boston, MA

P23 **WITHDRAWN**

P24 **WITHDRAWN**

P25 **PARASITIC INFECTION ALTERS THE QUALITY OF THE IMMUNE RESPONSE TO HIV-1 VACCINES**

J. D. Boyer¹, R. G. Nelson¹, T. M. Robinson¹, D. Artis², P. Scott²

¹Pathology, University of Pennsylvania, Philadelphia, PA, ²School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA

POSTER GROUP 4:

THERAPEUTIC VACCINES

P26 **PRE-CLINICAL ASSAY DEVELOPMENT FOR IMMUNOLOGICAL SCREENING OF A THERAPEUTIC VACCINE CANDIDATE: EVALUATION OF T-CELL RESPONSES TO CYP1B1 P450**

M. Matijevic, J. Sathiyaseelan, M. L. Hedley, J. Lathey
ZYCOS Inc., Lexington, MA

P27 **VIRUS BASED VACCINES FOR CANCER THERAPY**

J. D. Nieland
Preclinical Development, Medigene AG, Munich, GERMANY

P28 **HSV VECTORS FOR CANCER AND INFECTIOUS DISEASE IMMUNOTHERAPY**

Y. McGrath¹, S. Burton¹, S. Thomas¹, C. Lilley², P. Reay¹, R. Coffin¹

¹Biovex Ltd, Abingdon, UNITED KINGDOM, ²University College London, London, UNITED KINGDOM

P29 **IS CROHN'S DISEASE TREATABLE WITH THERAPEUTIC AUTOVACCINES?**

O. J. Nolte¹, H. E. Weiss¹, U. Rütger², H. G. Sonntag¹

¹Hygiene-Institut, Heidelberg, GERMANY, ²Solitude Klinik, Ludwigsburg, GERMANY

Fifth Annual Conference

FINAL PROGRAM

POSTER GROUP 5: CLINICAL STUDIES AND VACCINE SAFETY

- P30 FACTORS ASSOCIATED WITH (LACK OF) INFLUENZA VACCINATION AMONG HEALTH CARE WORKERS IN GERMANY**
U. Buchholz
Infektionsepidemiologies, Robert Koch Institute, Berlin, GERMANY
- P31 HYPERSENSITIVITY TO THIMEROSAL IN THE SKIN-TEST ANTIGEN COCCIDIOIDIN**
R. F. Hector¹, K. Earhart², B. Hale², M. Calloway², N. M. Ampel³, G. W. Rutherford¹, C. Lindan¹
¹Epidemiology & Biostatistics, UCSF, San Francisco, CA, ²Section of Infectious Diseases, Naval Medical Center, San Diego, CA, ³Section of Infectious Diseases, S. Arizona VAHSC, Tucson, AZ.
- P32 PARENTS WANT TO BE OFFERED THE VARICELLA VACCINE WHATEVER THEIR PHYSICIAN'S OPINION**
G. De Serres, L. Rochette, B. Duval, N. Boulianne
INSPQ, Quebec, PQ, CANADA
- P33 THE POSTMARKETING SAFETY REVIEW OF REPORTS OF HERPES ZOSTER AFTER THE ADMINISTRATION OF VARIVAX® [VARICELLA VIRUS VACCINE LIVE (OKA/MERCK)]**
S. Galea¹, A. Sweet¹, A. Gershon², P. LaRussa², S. Steinberg², S. Music¹, R. Sharrar¹
¹Merck & Co. Inc., West Point, PA, ²Columbia University College of Physicians and Surgeons, New York, NY
- P34 DESIGNING TRIALS TO DETECT HERD IMMUNITY EFFECTS FOR NONTYPEABLE HAEMOPHILUS INFLUENZAE VACCINES**
J. S. Koopman¹, X. Lin²
Hygiene Institute, Heidelberg, Germany
- P35 PROMOTING PUBLIC/PRIVATE PARTNERSHIPS: A MODEL OF PUBLIC HEALTH PARTICIPATION IN CLINICAL TRIAL RESEARCH**
S. J. Marks, MPA¹, L. Squires¹, P. Barrett¹, M. C. Caldwell, MD, MPH²
¹Communicable Disease Control Division, Dutchess County Department of Health, Poughkeepsie, NY, ²Dutchess County Department of Health, Poughkeepsie, NY
- P36 VOLUNTEER RECRUITMENT FOR PHASE I HIV VACCINE CLINICAL TRIALS IN NAIROBI, KENYA**
G. S. O. M. Omosa-Manyonyi, Sr.
Medical Microbiology - Kenya AIDS Vaccine Project, University of Nairobi, Nairobi, KENYA
- P37 WITHDRAWN**

on Vaccine Research

FINAL PROGRAM

P38 CONSIDERATIONS FOR FUTURE HAV VACCINE DEVELOPMENT

G. Raychaudhuri
FDA, Rockville, MD

P39 BCG SCAR AND POSITIVE TUBERCULIN REACTION ASSOCIATED WITH REDUCED CHILD MORTALITY IN WEST AFRICA. A NON-SPECIFIC BENEFICIAL EFFECT OF BCG?

M. Garly¹, C. L. Martins², C. Balé², M. A. Baldé², K. L. Hedegaard¹, P. Gustafsson², I. M. Lisse², H. C. Whittle³, P. Aaby²

¹*Department of Epidemiology Research, Statens Serum Institut, Copenhagen, DENMARK,*
²*Projecto de Saúde, Bandim, Bissau, GUINEA-BISSAU,* ³*Medical Research Laboratories, Fajara, GAMBIA*

P40 WITHDRAWN

P41 LIFE, HISTORY AND HEALTH PREDICTS VACCINE-INDUCED CYTOKINE PRODUCTION

M. S. Hayney¹, G. D. Love¹, J. M. Buck², D. Muller¹

¹*University of Wisconsin, Madison, WI,* ²*University of Minnesota, Minneapolis, MN*

P42 ESTABLISHMENT OF MINIMUM PROTECTIVE THRESHOLD SERUM ANTIBODY TITER TO RESPIRATORY SYNCYTIAL VIRUS (RSV) ASSOCIATED HOSPITALIZATION (RSV-AH)

P. A. Piedra¹, A. M. Jewell¹, S. G. Cron², W. P. Glezen¹, P. W. Hiatt²

¹*Molecular Virology & Microbiology, Baylor College of Medicine, Houston, TX,*
²*Pediatrics, Baylor College of Medicine, Houston, TX.*